688626 Xiangyu Medical
- 29.51
- -0.08-0.27%
Xiangyu Medical News
Express News | The Xiangyu medical electromagnetic stimulation therapy instrument has obtained the national medical instruments registration certificate.
Xiangyu Medical (688626.SH): has repurchased a total of 3.0000% of the company's shares.
On December 27th, Gelonghui reported that Xiangyu Medical (688626.SH) announced that, in light of the previous two share repurchase plans, as of December 27, 2024, the company's dedicated repurchase securities Account has cumulatively repurchased 4,800,000 shares through centralized bidding transactions, accounting for 3.0000% of the company's total share capital of 160,000,000 shares, of which 4,380,000 shares were repurchased during the implementation period of the company's first two repurchase plans.
Xiangyu Medical Appoints Chair
Xiangyu Medical (688626.SH): Key technical staff member Ma Denwei has left.
Xiangyu Medical (688626.SH) announced that the company's core technician, Ma Denwei, has resigned from the company for personal reasons...
Xiángyǔ Medical (688626.SH): He Yongzheng was elected as Director.
On December 19th, Long Guang Hui reported that Xiang Yu Medical (688626.SH) announced that Mr. He Yongzheng was elected as the Chairman of the Third Board of Directors, with a term starting from the date of review and approval by this Board of Directors until the end of the term of the Third Board of Directors.
Xiangyu Medical (688626.SH): "Asia Vets Rehabilitation Equipment (Southwest) Sales Center Project" concludes.
Gelonghui reported on December 19 that Xiangyu Medical (688626.SH) held the first meeting of the third Board of Directors and the first meeting of the third Supervisory Board on December 19, 2024. They reviewed and approved the proposal regarding the completion of the company's fundraising projects and the permanent replenishment of working capital with the remaining funds after the completion of all fundraising projects. The company agreed to conclude the fundraising project "Asia Vets Rehabilitation Equipment (Southwest) Marketing Center Project" and the total remaining raised funds of 36.1245 million yuan (after deducting handling fees) from the conclusion of the five fundraising projects in the initial public offering.
Xiangyu Medical (688626.SH): Suzhou Jifeng, Fuzhou Jifeng, and their concerted actors are no longer shareholders holding more than 5% of the company.
On December 17, Gelonghui reported that Xiangyu Medical (688626.SH) announced that on December 17, 2024, it received a "Brief Report on Equity Changes" from Suzhou Jifeng, Fuzhou Jifeng, and Jiaxing Jifeng No. 1. Suzhou Jifeng and Fuzhou Jifeng collectively reduced their shareholding in the company by 400,200 shares through centralized bidding trades from December 9 to December 16, 2024, accounting for 0.250125% of the company's total share capital. After this equity change, Suzhou Jifeng, Fuzhou Jifeng, and their concerted party Jiaxing Jifeng No. 1 together Hold 7,999,920 shares of the company, accounting for the company's total shares.
Express News | Xiangyu Medical: The shareholding ratio of the Shareholder and its concerted actions has decreased to below 5%.
Xiangyu Medical (688626.SH): The layout in the field of brain-computer interface focuses mainly on mental health, EEG collection devices, and active training.
On December 5th, Gelonghui reported that Xiangyu Medical (688626.SH) stated on the interactive platform that the company's layout in the brain-computer interface area primarily focuses on mental health, EEG collection devices, active training, and other directions, with multiple products having entered the registration process. Mental health products are expected to be available for sale at the earliest this year, while products in the active training category are expected to obtain registration certificates next year, and EEG collection devices are expected to receive registration certificates in the first half of next year.
Xiangyu Medical (688626.SH): bought back 0.1058 million shares for the first time.
On November 26, Gloryhui announced that on November 26, 2024, Xiangyu Medical (688626.SH) repurchased 105,800 shares of the company for the first time through the Shanghai Stock Exchange trading system using centralized bidding trading method, accounting for 0.0661% of the total share capital of 160,000,000 shares. The highest repurchase price was 31.20 yuan/share, and the lowest price was 30.80 yuan/share. The total amount paid was RMB 3,271,257.28 (excluding transaction fees such as transaction commissions and transfer fees).
The delay in bidding at the hospital end has negatively impacted revenue. Xiangyu Medical is cultivating a second growth curve, with brain-machine products expected to be available for sale as early as this year.
① Due to delays in the bidding activities at the hospital level, Xiangyu Medical experienced a decline in revenue in the first three quarters of 2024. The company is increasing its marketing efforts in areas such as military, exports, home care, private health care, and off-site services; ② Xiangyu Medical's layout in brain-computer interfaces is mainly focused on non-invasive rehabilitation devices, with mental health products expected to be market-ready as early as this year.
Xiangyu Medical to Buy Back Up to 100 Million Yuan of Shares
Express News | Xiangyu Medical: Planning to repurchase shares of 50 million yuan to -0.1 billion yuan.
Shanghai SHY(688626): Performance continues to be under pressure, waiting quietly for the medical industry to recover.
Investment highlights: The company is a leading research and development enterprise in the domestic rehabilitation medical instruments industry. It mainly focuses on rehabilitation assessment (including evaluating muscle strength, neurological disorders, degree of functional loss, etc.), rehabilitation training (including rehabilitation training equipment for exercise, active and passive training, etc.).
Express News | The Development and Reform Commission of Henan Province held a symposium for private enterprises.
Xiangyu Medical Report for the Third Quarter of 2024
Xiayu Medical (688626.SH): The net income for the first three quarters was 73.4139 million yuan, a year-on-year decrease of 59.02%.
Gelonghui October 29th | Xiangyu Medical (688626.SH) announced that in the first three quarters of 2024, revenue was 0.507 billion yuan, a decrease of 6.50% year-on-year; net income attributable to shareholders of the listed company was 73.4139 million yuan, a decrease of 59.02% year-on-year; basic earnings per share was 0.47 yuan.
Express News | The Medical medical 'spray gun for a low-temperature cryotherapy device' has been granted a patent.
Express News | Xiangyu Medical: Shareholders intend to reduce their total shareholding by no more than 1.99% of the company's shares.
Xiangyu Medical (688626.SH): has an early layout in the brain-computer interface field, and is still mainly non-invasive.
Gelonghui October 22丨 Xiangyu Medical (688626.SH) stated on the interactive platform that the company has laid out in the brain-computer interface field early, still mainly non-invasive at present, has applied for many patents, and some patents have been authorized. Various work is progressing in an orderly manner: 1. Products: brainwave acquisition device, targeting neonatal brain monitoring, brain attention issues, anxiety, depression, and emotional control issues, forming an integrated solution for brain function diagnosis and treatment. The product has entered the registration testing stage, and is expected to gradually obtain certification in the first half of next year; 2. Independent technology and talents: introduced well-known domestic experts in the field of mental health and psychology.
No Data
